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MaOBJECTIVES The aim of this study was to review randomized controlled trials (RCTs) using cardiac magnetic resonance
(CMR) to assess myocardial infarct (MI) size in reperfused patients with ST-segment elevation myocardial infarction (STEMI).
BACKGROUND There is limited guidance on the use of CMR in clinical cardioprotection RCTs in patients with STEMI
treated by primary percutaneous coronary intervention.
METHODS All RCTs in which CMR was used to quantify MI size in patients with STEMI treated with primary
percutaneous coronary intervention were identiﬁed and reviewed.
RESULTS Sixty-two RCTs (10,570 patients, January 2006 to November 2016) were included. One-third did not report
CMR vendor or scanner strength, the contrast agent and dose used, and the MI size quantiﬁcation technique. Gado-
pentetate dimeglumine was most commonly used, followed by gadoterate meglumine and gadobutrol at 0.20 mmol/kg
each, with late gadolinium enhancement acquired at 10 min; in most RCTs, MI size was quantiﬁed manually, followed by
the 5 standard deviation threshold; dropout rates were 9% for acute CMR only and 16% for paired acute and follow-up
scans. Weighted mean acute and chronic MI sizes (#12 h, initial TIMI [Thrombolysis in Myocardial Infarction] ﬂow grade
0 to 3) from the control arms were 21  14% and 15  11% of the left ventricle, respectively, and could be used for future
sample-size calculations. Pre-selecting patients most likely to beneﬁt from the cardioprotective therapy (#6 h, initial
TIMI ﬂow grade 0 or 1) reduced sample size by one-third. Other suggested recommendations for standardizing CMR in
future RCTs included gadobutrol at 0.15 mmol/kg with late gadolinium enhancement at 15 min, manual or 6-SD threshold
for MI quantiﬁcation, performing acute CMR at 3 to 5 days and follow-up CMR at 6 months, and adequate reporting of the
acquisition and analysis of CMR.
CONCLUSIONS There is signiﬁcant heterogeneity in RCT design using CMR in patients with STEMI. The authors provide
recommendations for standardizing the assessment of MI size using CMR in future clinical cardioprotection RCTs. (J Am Coll
Cardiol Img 2017;10:230–40) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
AAR = area at risk
CMR = cardiac magnetic
resonance
FWHM = full width half
maximum
GBCA = gadolinium-based
contrast agent
Gd-DOTA = gadoterate
meglumine
Gd-DTPA = gadopentetate
dimeglumine
LGE = late gadolinium
enhancement
LV = left ventricular
MI = myocardial infarct
MSI = myocardial salvage index
MVO = microvascular
obstruction
PPCI = primary percutaneous
coronary intervention
RCT = randomized controlled
trial
STEMI = ST-segment elevation
ardial infarction
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231reperfusion injury to reduce MI size in patients with
STEMI treated with PPCI (3).
Late gadolinium enhancement (LGE) by CMR is
considered the gold standard for MI size quantiﬁcation
(4). MI size (5), microvascular obstruction (MVO) (6),
and myocardial salvage (7) assessed by CMR per-
formed in the ﬁrst few days post-PPCI have all been
shown to be strongly prognostic. As a result, CMR is
increasingly being used for surrogate endpoints in
RCTs (3). A recent meta-analysis of 2,632 patients from
10 RCTs found that MI size measured by CMR or single-
photon computed tomography within 1 month post-
PPCI showed that for every 5% increase in MI size,
there was a 20% increase in the relative hazard ratio for
1-year hospitalization for heart failure and all-cause
mortality (5).
Despite CMR endpoints being quite robust and
their ability to keep sample size small (3), there is
limited guidance on its use. In this study, we
reviewed all published RCTs in this ﬁeld so far, and
we provide recommendations for standardizing the
use of CMR in future clinical cardioprotection RCTs.
METHODS
We performed a comprehensive systematic search in
the MEDLINE and Embase databases via Ovid up to
November 23, 2016. PubMed and the Web of Science,
editorials, and the reference lists of included RCTs
were also screened. Further details of the search
terms and the study screening and selection as per
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses are provided in the Online Ap-
pendix. The ﬂow diagram is shown in Figure 1.
The inclusion criteria were as follows: 1) RCTs
investigating cardioprotective strategies aimed at
reducing MI size; 2) including patients presenting
within 12 h of symptom onset; 3) MI size measured by
CMR; and 4) RCTs with full-text reports in English.
The exclusion criteria were as follows: 1) RCTs
selecting patients on the basis of admission ejection
fraction; 2) RCTs performing post hoc analysis on
other included RCTs; 3) observational studies; and
4) RCTs only reporting left ventricular (LV) ejection
fraction by CMR.
STUDY SELECTION AND DATA EXTRACTION. Four
authors (H.B., M.H.-H., S.W., R.M.M.) independently
identiﬁed suitable RCTs from the screened reports
and extracted all data. Data on study characteristics,
patient eligibility criteria, CMR scanner and contrast
agent used, MI size quantiﬁcation technique used,
and mean MI size and SD in the control arm were
collected. RCTs reporting both acute MI size
and follow-up MI size ($1 month) were recorded.The primary outcome of interest was MI size,
expressed as a percentage of LV volume or
mass (%LV).
STATISTICAL ANALYSIS. Categorical data are
reported as frequencies and percentages. For
sample size calculation, to ensure normally
distributed MI size in the control arms, only
RCTs reporting mean MI size as %LV were
included, and an unpaired Student t test was
used. Only RCTs including STEMI in all cor-
onary territories were included, and they
were grouped according to duration of
symptoms (<6 or <12 h) and TIMI (Throm-
bolysis In Myocardial Infarction) ﬂow grade
0 or 1 or 1 to 3 in the culprit arteries pre-PPCI
if at least 3 RCTs were present in the sub-
groups. The mean and SD from each control
arm were weighted against its respective
sample size to obtain representative pooled
mean acute and follow-up MI sizes using
RevMan version 5.2 (Nordic Cochrane Center,
Copenhagen, Denmark). Sample-size calcu-
lation was performed for 90% power, a
2-sided alpha value of 0.05, and expected
effect sizes of 20%, 25%, and 30% using Stata/
IC version 12.1 (StataCorp LP, College Station, Texas).
The expected sample sizes were provided for each
group after accounting for potential dropouts.
RESULTS
Our initial search identiﬁed 399 reports and 62 RCTs,
involving 10,570 patients, that met the inclusion
criteria. Details of the 62 included RCTs are provided
in Online Table 1.
CHARACTERISTICS OF THE RCTs. The number of
RCTs using CMR has steadily increased since 2009
(Figure 2). There was an average of 8 RCTs reported
per year between 2010 and 2016. The majority of RCTs
came from Europe (41 of 62 [66%], 6,880 patients),
and 35 of 62 (56%) were single-center RCTs.
MI size as %LV was reported in 44 RCTs (71%). Five
RCTs (8%) reported MI size as percentage of the area
at risk (AAR), 5 (8%) in grams, and 7 RCTs (12%) re-
ported myocardial salvage index (MSI).
The majority of RCTs included: 1) patients pre-
senting within 12 h of symptom onset (32 of 62 [52%]);
2) STEMI in all epicardial territories (49 of 62 [79%]);
and 3) patients with all TIMI ﬂow pre-PPCI (33 of 62
[53%]), as shown in Figure 3.
Forty-six of the RCTs (74%) used 1.5-T scanners,
and a minority (2 RCTs [3%]) used 3-T scanners.
Four RCTs (7%) used a combination of 1.5- and 3-T
scanners. Ten RCTs (16%) did not specify the ﬁeld
myoc
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow Diagram
PRISMA 2009 Flow Diagram
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This ﬁgure shows the process of identifying, screening, and selecting the randomized controlled trials (RCTs) included in this study. Of 399
studies screened, 62 RCTs eventually met the inclusion criteria. PRISMA ¼ Preferred Reporting Items for Systematic Reviews and Meta-
Analyses.
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232strength of the CMR scanners used, and 8 of 10 (80%)
of those were multicenter RCTs.
Thirty-six of the RCTs (58%) used single CMR
vendors, and 7 RCTs (11%) used multivendor scanners
at different recruitment sites. Nineteen RCTs (31%)
did not specify the vendors used, the majority of
which (15 RCTs [75%]) were multicenter RCTs.
Paired acute and follow-up CMR was performed in
26 RCTs (42%), acute CMR only in 24 RCTs (39%), and
follow-up CMR only in 12 RCTs (19%).
GADOLINIUM-BASED CONTRAST AGENT AND DOSE. Ga-
dopentetate dimeglumine (Gd-DTPA) (Magnevist,
Bayer Healthcare, Berlin, Germany), gadoterate
meglumine (Gd-DOTA) (Dotarem, Guerbet, Roissy CdG
Cedex, France), and gadobutrol (Gadovist, Bayer
Healthcare) were used in 18 (29%), 12 (19%), and 9
(14%) of the 62 RCTs, respectively. Nineteen of62 RCTs (31%) did not specify the gadolinium-based
contrast agent (GBCA) used, of which 15 of 19 (79%)
weremulticenter RCTs. Online Table 2 summarizes the
doses of the GBCAs and the reported timing for LGE
acquisition post-contrast. The most common doses for
Gd-DTPA (Magnevist), gadobutrol (Gadovist), and
Gd-DOTA (Dotarem) were similar at 0.20 mmol/kg,
with LGE acquisition starting at 10 min onward.
TIMING OF CMR ACQUISITION. The distribution of
the timings to acquire acute and follow-up CMR is
shown in Figure 4. Of 50 RCTs with acute CMR acqui-
sition, only 1 did not specify the exact timing of the
scan. There was a wide range of timings to acquire the
acute CMR scan, with the majority (82%) acquired
within the ﬁrst 7 days post-PPCI and the most common
timing being 3 to 5 days post-STEMI (15 of 50 RCTs
[30%]). There was also a wide range of timings (1 to 9
FIGURE 2 Number of Randomized Controlled Trials Published Each Year Since 2006
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This bar chart shows the gradual increase in the number of randomized controlled trials
(RCTs) published each year over the past 11 years.
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233months) to acquire follow-up MI size, with the most
common timing being 6 months (11 of 37 RCTs [30%]).
MI SIZE ANALYSIS. Seventeen of 25 of the multi-
center RCTs (68%) speciﬁed using a CMR core labo-
ratory. The majority of the RCTs (29 of 62 [47%]) used
specialist software (Qmass, Medis Medical Imaging
Solutions, Leiden, the Netherlands; CVI42, Circle
Cardiovascular Imaging Inc., Calgary, Canada;
Segment, Medviso, Lund, Sweden; and CAAS, Pie
Medical Imaging B.V., Maastricht, the Netherlands)
for MI size quantiﬁcation, 7 RCTs (11%) used the
scanners’ own software, and 5 of 62 (8%) used
shareware (ImageJ, National Institutes of Health,
Bethesda, Maryland; OsiriX, Geneva, Switzerland).
Twenty-one of 62 RCTs (34%) did not specify the
analysis tool used, of which 9 of 21 (43%) were
multicenter RCTs.
Manual contouring was the most commonly used
method (22 of 62 RCTs [36%]), followed by 5-SD (8
of 62 RCTs [13%]) and full width half maximum
(FWHM) (6 of 62 RCTs [10%]). Sixteen of 62 RCTs
(27%) did not specify the method used for MI
quantiﬁcation, of which 9 of 16 (56%) were multi-
center RCTs. Figure 5 shows the distribution of the
quantiﬁcation techniques for MI size used in these
RCTs.
DISTRIBUTION OF CULPRIT VESSEL AND TIMI FLOW
PRE-PPCI. Among the RCTs including all culprit
vessels (n ¼ 6,020), 45% of the patients had STEMI in
the left anterior descending coronary artery territory.
Among the RCTs including all TIMI ﬂow grades
(n ¼ 3,229), 73% of patients had TIMI ﬂow grades of
0 or 1 pre-PPCI.
EFFECT SIZE FOR REDUCTION IN MI SIZE IN RCTs
WITH POSITIVE RESULTS. Seventeen RCTs were
positive for a reduction in MI size. Of the RCTs
reporting MI size as %LV, the median reduction in
acute MI size was 34% (mode 35%; range 14% to 38%).
As for chronic MI size, both the median and mode
reduction in MI size were 18% (range 14% to 46%).
MI SIZE IN THE CONTROL ARM. RCTs reporting mean
 SD, including STEMI presenting within 6 or 12 h, in
all coronary territories, and with TIMI ﬂow grades of
0 or 1 or 0 to 3 pre-PPCI were selected to obtain
representative weighted mean MI size, expressed as
%LV in the control arm for both acute (20 RCTs) and
follow-up (18 RCTs) CMR (summarized in Online Ta-
bles 3 and 4). The expected sample sizes on the basis
of 20%, 25%, and 30% reductions in MI size are
summarized in Table 1. The expected sample sizes are
provided on the basis of 90% power and a 2-sided
alpha of 0.05.The estimated sample size was smallest for RCTs
including patients with STEMI within 6 h of symptom
onset and with pre-PPCI TIMI ﬂow grades of 0 or 1 and
was largest for RCTs recruiting patients within 12 h of
symptom onset and with any TIMI ﬂow grades pre-
PPCI, and this was driven by a wider SD in the latter
group. For the same effect size, RCTs planning to use
chronic MI would require on average 30% more pa-
tients than if acute MI were chosen as the endpoint.
DROPOUT RATES. In RCTs using CMR for the primary
endpoint, the average dropout rate was 9% for RCTs
using acute CMR only, 13% for RCTs acquiring follow-
up CMR only, and 16% for those with paired acute and
follow-up scans.
DISCUSSION
On the basis of the 62 RCTs reviewed, substantial
heterogeneity exists in trial design with respect to
patient selection, timing of acute and follow-up
scans, GBCA dose, timing of LGE acquisition, and
method for MI quantiﬁcation. Among those RCTs not
reporting scanner strength and vendor, GBCA used,
and software used for MI size quantiﬁcation, the
majority were multicenter RCTs.
The other major ﬁndings were as follows: 1) acute
CMR was most commonly performed at 3 to 5 days and
follow-up CMR at 6 months; 2) Gd-DOTA, gadobutrol,
and Gd-DTPA were most commonly used at a similar
dose of 0.20 mmol/kg, with LGE acquired at 10 min;
3) MI size was quantiﬁed manually in most RCTs,
FIGURE 4 Timing of Acute and Follow-Up CMR
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These 2 bar charts show the distribution of the timings of the (A) acute and (B) follow-up
cardiac magnetic resonance (CMR) in the randomized controlled trials (RCTs) included.
There was a wide range of timings for both scans, and the most common timings were 3 to
5 days for the acute scan and 6 months for the follow-up scan.
FIGURE 3 Distribution of RCTs by Inclusion of Patients on the Basis of Duration of Symptoms, Infarct-Related Artery Included, and TIMI
Flow Grade Pre–Primary Percutaneous Coronary Intervention
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These 3 pie charts show the percentage of randomized controlled trials (RCTs) including (A) patients on the basis of duration of symptoms, (B)
infarct-related artery, and (C) TIMI (Thrombolysis in Myocardial Infarction) ﬂow grade pre–primary percutaneous coronary intervention
(PPCI). The majority of the RCTs included patients presenting within 12 h of symptom onset, with ST-segment elevation myocardial infarction
in all coronary territories, and with all pre-PPCI TIMI ﬂow grades. LAD ¼ left anterior descending coronary artery; RCA ¼ right coronary
artery.
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234followed by the 5-SD threshold; 4) STEMI in the left
anterior descending coronary artery territory accoun-
ted for one-half and those with TIMI ﬂow grades of 0 or
1 accounted for three-quarters of all STEMIs entering
these RCTs and could be taken into consideration for
sample-size calculation in speciﬁc circumstances; 5)
for positive RCTs, themost commonly seen effect sizes
were 34% for acute MI and 18% for chronic MI
($1 month) size reduction; 6) using the control arms
from RCTs reporting mean MI size, theoretical sample
sizes for future clinical cardioprotection studies were
provided; and 7) the dropout rate was highest for RCTs
performing paired acute and follow-up scans, followed
by those performing follow-up CMR only, and smallest
in the RCTs performing acute CMR only.
ROBUSTNESS OF CMR-DERIVED SURROGATE
ENDPOINTS. CMR has recently emerged as a robust
tool not only for MI size quantiﬁcation (5) but also to
provide additional information on the AAR (to derive
MSI) (8), LV ejection fraction (9), andMVO (6,10) from a
single scan. MI size, myocardial salvage, and LV ejec-
tion fraction by CMR are highly reproducible (reducing
sample size) (8,9,11,12) and are strongly linked to
prognosis (5,7,13–15). Furthermore, with recent
advances in mapping techniques, multiparametric
information can be obtained from native (for the AAR)
(16) and post-contrast T1 maps (to derive extracellular
volume fraction maps to interrogate the remote
FIGURE 5 Quantiﬁcation Techniques for MI Size
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The most common myocardial infarct (MI) size quantiﬁcation method was manual
delineation, followed by 5-SD and full width half maximum (FWHM). However, 27% of
randomized controlled trials did not specify the method used.
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235myocardium) (17,18), T2 maps (AAR) (16) and T2* maps
(intramyocardial hemorrhage and residual myocardial
iron) (19,20). These additional mapping parameters
provide more robust measurement of the edema-
based AAR (when compared with angiographic
scores) (21), pathophysiological insights in post-STEMI
LV remodeling (17–19,22), and prognostic information
(20). Unlike single-photon emission computed
tomography, CMR has superior spatial resolution (14),
does not involve radiation, and requires only a single
examination, when the patient is relatively stable.
Furthermore, MVO and MI size by CMR have been
shown to bemore prognostic compared withMI size by
single-photon emission computed tomography (14).
The superior spatial resolution of CMR also allows
detection of small MIs that could be missed by relying
on wall motion abnormalities on echocardiography
alone (23), interrogation of the peri-infarct zone (24),
and hypointense core of the MVO (25), which are all
prognostic (24–26). Therefore, it is not surprising that
CMR endpoints have gained popularity for use in
several RCTs (3).
OPTIMAL TIMING OFACUTE CMR POST-STEMI. Preclinical
studies have shown that performing CMR too early
post-reperfusion (day 1) leads to an overestimation of
MI size because of a combination of edema and partial
volume effect (27). In the clinical setting, acute MI
size has also been shown to be dynamic and to
decrease signiﬁcantly in size between days 1 and 7
(28,29) but is stable between days 3 and 4 (8).
Recently, Carrick et al. (30) showed that acute MI size
was stable between days 1 and 3 and subsequently
reduced in size by day 10. Furthermore, late MVO has
also been shown to be stable between days 1 and 3
and to reduce in size by day 10 (20), and the persis-
tence of late MVO at 1 week following STEMI was
more prognostic (31). The detection of intra-
myocardial hemorrhage has been shown to peak at
day 3, and reduced in size and incidence by day 10,
and intramyocardial hemorrhage was more prog-
nostic than MVO (20).
There is no established method to assess the AAR
(a pre-requisite to calculate MSI) in the clinical setting
by CMR. T2 mapping has recently emerged as more
robust than T2-weighted imaging for assessing
edema-based AAR (32). Some controversies exist as to
whether edema within the AAR follows a bimodal
pattern (33) and whether T2-weighted imaging
delineates the AAR at all (34) in the preclinical
setting. It was previously believed that edema was
stable in the ﬁrst week of a MI (28) using T2-weighted
imaging. However, Carrick et al. (30) recently showedthat the extent of myocardial edema followed a
unimodal pattern and peaked at day 3 in patients.
On the basis of the clinical research published so far,
if the CMR scan is performed at <3 days, MI size would
be overestimated and AAR would be underestimated.
If the CMR scan is performed at >5 days, the edema-
based AAR may be underestimated. Therefore,
acquiring the acute CMR scan at 3 to 5 days following
STEMI, as performed in most cardioprotection RCTs in
this review, may be the optimal time to undertake the
acute CMR scan, as illustrated in Figure 6.
OPTIMAL TIMING OF FOLLOW-UP CMR. Chronic MI
size has been shown to be stable when performed
between 1 month and up to 1 year (31). Paired acute
and follow-up scans also provide information on
post-STEMI LV remodeling, which occurs by 2
months, although the process may continue for up to
1 year (31). However, waiting too long between the
acute and follow-up CMR scans may increase the
likelihood of patients’ dropping out of the studies.
Therefore, in RCTs aiming to assess both chronic MI
size and LV remodeling, performing the follow-up
scan at 6 months, as done in most of the RCTs
reviewed in this study, would be optimal.
TABLE 1 Sample-Size Estimation for Future RCTs Investigating Therapy for Reducing MI Size by CMR
Patient Inclusion Criteria
Pooled MI Size by CMR in the Control Group From
Previous RCTs (as %LV)
Sample Size per Group After Accounting for Potential Dropouts (9% for Acute CMR and
13% for Follow-Up CMR) for 90% Power With a 2-Sided Alpha of 0.05
For an Effect Size of 20% For an Effect Size of 25% For an Effect Size of 30%
TIMI Flow
Pre-PPCI
Symptom
Onset (h)
Weighted Mean
(95% CI) SD
Number of Studies
(Number of Patients) MI Size Sample Size MI Size Sample Size MI Size Sample Size
Acute scan only (including STEMI in all coronary territories)
0 or 1 #6 22 (20–24) 12 3 RCTs (136 patients):
Chan (2012)
Garcia-Dorado (2014)
Waltenberg (2014)
17.6 171 16.5 110 15.4 76
0 or 1 #12 24 (22–26) 13 3 RCTs (189 patients):
Freixa (2011)
Mewton (2013)
Siddiqi (2014)
White (2015)
19.2 169 18.0 108 16.8 75
0–3 #12 21 (19–22) 14 5 RCTs (305 patients):
Yoon (2013)
Ko (2014)
Hoole (2015)
McCann (2015)
Liu (2016)
16.8 265 15.8 164 14.7 85
Chronic scan only (including STEMI in all coronary territories)
0 or 1 #6 15 (14–17) 9 4 RCTs (152 patients):
Tarantini (2012)
Atar (2015)
Waltenberg (2014)
Roos (2016)
12.0 215 11.3 215 10.5 96
0 or 1 #12 15 (13–16) 9 4 RCTs (186 patients):
Lonborg (2010)
Freixa (2011)
Lonborg (2012)
Siddiqi (2014)
12.0 215 11.3 216 10.5 96
0–3 #12 15 (14–17) 11 4 RCTs (284 patients):
Song (2009)
Ranchord (2012)
Roolvink (2016)
Ko (2014)
12.0 320 11.3 205 10.5 142
The references for the RCTs included in each row are provided in Online Table 5.
CI ¼ conﬁdence interval; CMR ¼ cardiac magnetic resonance; MI ¼ myocardial infarction; %LV ¼ percentage of left ventricular mass or volume; PPCI ¼ primary percutaneous coronary intervention;
RCT ¼ randomized controlled trial; TIMI ¼ Thrombolysis in Myocardial Infarction.
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236OPTIMAL GBCA DOSE AND TIMING OF LGE
ACQUISITION. Gadobutrol has been shown to delin-
eate the infarcted myocardium better from the blood
pool (better contrast-to-noise ratio) compared with
Gd-DTPA (35) and Gd-DOTA (36) in chronic MI.
Furthermore, gadobutrol has been shown to differ-
entiate the infarcted myocardium from the LV
blood pool as early as 9 min. The recommended
relaxivity-adjusted standard doses are 0.22 mmol/kg
for Gd-DOTA (36), 0.15 mmol/kg for gadobutrol
(35,36), and 0.20 mmol/kg for Gd-DTPA (35).
Acquiring LGE too early (<8 min) post–GBCA
administration has been shown to result in over-
estimation of MI size (37), and acquiring LGE at 25
min for acute MI size was a better predictor of LV
recovery (38). In most RCTs included in this study,
LGE imaging was performed at 10 min. Performing
comprehensive CMR in patients with STEMI can betime-consuming, and to minimize patient discom-
fort and prevent dropout of patients, every attempt
is made to keep scan time to a minimum. Therefore,
acquiring LGE images 15 min post–GBCA admin-
istration in future RCTs would be a good
compromise.
METHOD FOR QUANTIFYING MI SIZE. There is currently
no established gold-standard semiautomated tech-
nique for MI size quantiﬁcation. Manual contouring is
considered the reference standard (4,11), but it can be
time-consuming and may be subjective. The 5-SD
approach is currently recommended, as it may
improve reproducibility (4).
Although FWHM has emerged as being the most
reproducible (39,40), it has been shown to underes-
timate acute and chronic MI size (40). Some studies
showed that 5-SD was promising (39–41), but others
FIGURE 6 Evolution of Edema-Based Area at Risk, MI Size, Microvascular Obstruction,
and Intramyocardial Hemorrhage in Patients With ST-Segment Elevation Myocardial
Infarction Within the First 10 Days Post-Reperfusion
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This is a schematic representation of the evolution edema-based area at risk (AAR) (based
on ﬁndings from Carrick et al. [30] and Desch et al. [8]), myocardial infarct (MI) size
(Carrick et al. [30] and Desch et al. [8]), microvascular obstruction (MVO) (Carrick et al.
[20,30]), and intramyocardial hemorrhage (IMH) (Carrick et al. [20,30]) within the ﬁrst
10 days post-reperfusion, expressed as percentage left ventricular volume or mass
(%LV). *The scale on the y-axis is an approximation. LGE ¼ late gadolinium
enhancement; PPCI ¼ primary percutaneous coronary intervention.
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237showed that it overestimated MI size (42,43). The
n-SD technique requires the remote myocardium to
be appropriately nulled and free of artifacts. A
manual region of interest is required in the remote
myocardium, and this can be a source of variability.
The Otsu technique does not require a region of in-
terest as a reference and has been shown to accu-
rately delineate MI size (40). But 2 subsequent studies
showed that Otsu overestimated MI size (42,43).
The most common method used to quantify MI size
in the RCTs was manual contouring, followed by 5-SD
and FWHM. We recently showed that FWHM un-
derestimates chronic MI size in those with MVO on
the acute scan because of very high extracellular
volume in the area previously occupied by MVO
and should be avoided for RCTs assessing chronic MI
size (42).
The 6-SD method appears the most promising and
has been shown to have the highest accuracy to pre-
dict segment wall recovery in patients with chronic
myocardial infarction (44) and is similar to manual
quantiﬁcation in patients with both acute and chronic
myocardial infarction (39,42). The 6-SD approach
also performed well when using 2 different LGE
sequences (42).
IMPACT OF PATIENT SELECTION AND TIMING OF
CMR ON SAMPLE SIZE. In Table 1 we provide guid-
ance for expected sample sizes, depending on the
desired effect size, after accounting for expected
dropout rates when planning future RCTs. For
example, if an RCT includes patients with all TIMI
ﬂow grades pre-PPCI and presenting within 12 h of
symptom onset, for an expected 25% reduction in
acute MI size, 164 patients would be needed in each
arm. If the endpoint were to be changed to chronic MI
size, then for the same effect size, the sample size for
each arm would increase to 205. However, we have
observed that the realistic effect size for chronic
MI size on average is lower (18%), and this would
increase the sample size further.
If only patients with pre-PPCI TIMI ﬂow grades of
0 or 1 and within 6 h of symptom onset were included,
the sample size for each arm would be reduced by
about one-third to 110 patients. However, only three-
quarters of patients with STEMI present with TIMI
ﬂow grades of 0 or 1, and therefore at least one-third
more patients would need to be screened to achieve
the desired sample size.
RECOMMENDATIONS FOR FUTURE CARDIOPROTECTION
RCTs IN PATIENTS WITH STEMI. Careful patient
selection to include those patients most likely
beneﬁt from a novel cardioprotective therapy for
reducing MI size (ischemic time <6 h and pre-PPCITIMI ﬂow grade 0 or 1) can reduce sample size by
one-third, but more patients would need to be
screened.
Acute MI size should be preferred to chronic MI
size as a surrogate endpoint, because acute MI size is
already prognostic (5), and this would reduce sample
size and result in fewer dropouts.
Acute CMR should ideally be performed on day 3,
4, or 5. When a follow-up scan is planned, 6 months
would be the optimal timing for data on both chronic
MI size and LV remodeling.
The preferred GBCA should be gadobutrol (superior
contrast-to-noise ratio) (35) at 0.15 mmol/kg (recom-
mended relaxivity-adjusted standard dose) (35,36),
with LGE performed at 15 min.
Manual quantiﬁcation of MI size by experienced
operators at a core laboratory level is considered the
gold standard (4). When this is not practical, the 6-SD
threshold would be an alternative option. However,
any semiautomated technique is likely to be inﬂu-
enced by the LGE image quality, and therefore, each
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Among RCTs using MI size by CMR as a surrogate
to assess the effectiveness of cardioprotective
strategies, signiﬁcant heterogeneity exists in the
performance of CMR and the analysis of MI size.
Furthermore, one-third of the RCTs did not provide
details on the CMR scanner used, the contrast agent
and dose administered, or the method used to
quantify MI size.
TRANSLATIONAL OUTLOOK: There is a need to
standardize the acquisition of CMR images and the
analysis of MI size, to optimize the design of future RCTs,
andwe have provided some initial recommendations.We
have also provided representative MI sizes for patients in
the control arms of the RCTs, which could be used for
sample-size calculations. Future RCTs should report
details on the execution of the scans and the methods
used for MI size quantiﬁcation, to facilitate comparison
among RCTs.
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238center may need to validate the performance of these
semiautomated techniques at the respective center or
core laboratory.
In the absence of a gold-standard method for the
AAR, MI size should be reported as %LV, which has
also been shown to be prognostic (5). Although MSI is
reported to be a better surrogate, in adequately
powered RCTs, the AAR should be adequately
balanced in both arms, and therefore expressing MI
size as %LV would be acceptable.
Finally, all RCTs, in particular multicenter RCTs,
should provide adequate details on the execution
and quantiﬁcation of MI size in RCTs to allow fair
interpretation and comparison of study results and
provide more reliable MI size in the control arms for
future sample-size calculation.
STUDY LIMITATIONS. We included only RCTs in
this review, but some of the recommendations could
also be applied to observational studies to stan-
dardize the conduct of CMR, making comparison
among studies easier.
We concentrated only on MI size. Using MSI as a
surrogate endpoint is considered more sensitive to
assess the effectiveness of cardioprotective therapies
(45) and has recently been shown to reduce sample
size (46). However, given the lack of consensus
(33,34) and ongoing validation of the AAR method-
ologies, we did not evaluate the use of MSI in the
RCTs published so far.
MVO has been shown to be more prognostic than
MI size (15), but we did not assess the deﬁnition of
MVO in the included RCTs. However, if the perfor-
mance and quantiﬁcation of LGE for MI size were
standardized, this would also standardize MVO (late)
quantiﬁcation.
The recommended dose for gadobutrol is based on
the recommended relaxivity-adjusted standard dose,
and ideally a head-to-head comparison of the
different doses should be performed. However, this is
challenging in the acute MI setting, given the dy-
namic nature of MI size within the ﬁrst week. The
most commonly seen effect sizes for acute and
chronic MI size are related to the intervention they
were subjected to and are meant to serve as a guidefor realistic effect sizes in the acute and chronic MI
setting.
CONCLUSIONS
There is signiﬁcant heterogeneity in the design of
RCTs using CMR to quantify MI size in clinical car-
dioprotection studies in reperfused patients with
STEMI. Here, we have provided insights from RCTs
published so far and have offered recommendations
for standardizing the assessment of MI size by CMR to
optimize the design of future studies assessing the
efﬁcacy of cardioprotective strategies.
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